edwards lifesciences corp. - EW
EW
Close Chg Chg %
71.20 0.32 0.45%
Closed Market
71.52
+0.32 (0.45%)
Volume: 3.25M
Last Updated:
Apr 17, 2025, 3:59 PM EDT
Company Overview: edwards lifesciences corp. - EW
EW Key Data
| Open $71.20 | Day Range 70.65 - 72.15 |
| 52 Week Range 58.93 - 95.25 | Market Cap $41.90B |
| Shares Outstanding 585.76M | Public Float 574.31M |
| Beta 1.15 | Rev. Per Employee N/A |
| P/E Ratio 49.01 | EPS $2.46 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.86M |
EW Performance
| 1 Week | 3.07% | ||
| 1 Month | 1.52% | ||
| 3 Months | 2.51% | ||
| 1 Year | -16.77% | ||
| 5 Years | -6.05% |
EW Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
32
Full Ratings ➔
About edwards lifesciences corp. - EW
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
EW At a Glance
Edwards Lifesciences Corp.
1 Edwards Way
Irvine, California 92614
| Phone | 1-949-250-2500 | Revenue | 5.44B | |
| Industry | Medical Specialties | Net Income | 874.60M | |
| Sector | Health Technology | Employees | 15,800 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
EW Valuation
| P/E Current | 49.013 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 50.726 |
| Price to Sales Ratio | 8.156 |
| Price to Book Ratio | 4.358 |
| Price to Cash Flow Ratio | 81.811 |
| Enterprise Value to EBITDA | 25.728 |
| Enterprise Value to Sales | 7.565 |
| Total Debt to Enterprise Value | 0.017 |
EW Efficiency
| Revenue/Employee | 344,272.152 |
| Income Per Employee | 55,354.43 |
| Receivables Turnover | 7.478 |
| Total Asset Turnover | 0.485 |
EW Liquidity
| Current Ratio | 4.176 |
| Quick Ratio | 3.454 |
| Cash Ratio | 2.644 |
EW Profitability
| Gross Margin | 78.798 |
| Operating Margin | 26.552 |
| Pretax Margin | 28.46 |
| Net Margin | 16.079 |
| Return on Assets | 12.498 |
| Return on Equity | 16.829 |
| Return on Total Capital | 13.094 |
| Return on Invested Capital | 15.57 |
EW Capital Structure
| Total Debt to Total Equity | 7.001 |
| Total Debt to Total Capital | 6.543 |
| Total Debt to Total Assets | 5.362 |
| Long-Term Debt to Equity | 6.767 |
| Long-Term Debt to Total Capital | 6.324 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Edwards Lifesciences Corp. - EW
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 5.23B | 5.38B | 6.00B | 5.44B | |
Sales Growth
| +19.29% | +2.86% | +11.56% | -9.41% | |
Cost of Goods Sold (COGS) incl D&A
| 1.23B | 1.17B | 1.44B | 1.15B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 163.30M | 166.80M | 145.00M | 155.20M | |
Depreciation
| 155.60M | 161.10M | 138.90M | 149.60M | |
Amortization of Intangibles
| 7.70M | 5.70M | 6.10M | 5.60M | |
COGS Growth
| +11.55% | -4.79% | +23.26% | -19.84% | |
Gross Income
| 4.01B | 4.22B | 4.57B | 4.29B | |
Gross Income Growth
| +21.88% | +5.21% | +8.32% | -6.13% | |
Gross Profit Margin
| +76.57% | +78.31% | +76.04% | +78.80% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.40B | 2.51B | 2.90B | 2.84B | |
Research & Development
| 903.10M | 945.20M | 1.07B | 1.05B | |
Other SG&A
| 1.49B | 1.57B | 1.82B | 1.79B | |
SGA Growth
| +20.33% | +4.87% | +15.27% | -1.87% | |
Other Operating Expense
| - | - | - | (300.00K) | - |
Unusual Expense
| (130.90M) | (1.60M) | 173.20M | 41.60M | |
EBIT after Unusual Expense
| 1.74B | 1.70B | 1.50B | 1.40B | |
Non Operating Income/Expense
| (14.50M) | 89.60M | 126.10M | 165.20M | |
Non-Operating Interest Income
| 17.40M | 35.50M | 67.20M | 120.30M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 24.80M | 26.20M | 24.50M | 19.80M | |
Interest Expense Growth
| +11.71% | +5.65% | -6.49% | -19.18% | |
Gross Interest Expense
| 24.80M | 26.20M | 24.50M | 19.80M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 1.70B | 1.77B | 1.60B | 1.55B | |
Pretax Income Growth
| +85.67% | +3.84% | -9.58% | -3.13% | |
Pretax Margin
| +32.53% | +32.84% | +26.61% | +28.46% | |
Income Tax
| 198.90M | 245.50M | 198.70M | 152.10M | |
Income Tax - Current - Domestic
| 150.30M | 429.70M | 375.40M | 289.10M | |
Income Tax - Current - Foreign
| 92.60M | 66.70M | 85.30M | 25.80M | |
Income Tax - Deferred - Domestic
| (34.80M) | (246.60M) | (241.70M) | (148.80M) | |
Income Tax - Deferred - Foreign
| (9.20M) | (4.30M) | (20.30M) | (14.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 1.50B | 1.52B | 1.40B | 1.40B | |
Minority Interest Expense
| - | - | (3.00M) | (4.90M) | - |
Net Income
| 1.50B | 1.52B | 1.40B | 1.40B | |
Net Income Growth
| +82.55% | +1.25% | -7.85% | -0.11% | |
Net Margin Growth
| +28.73% | +28.28% | +23.35% | +25.75% | |
Extraordinaries & Discontinued Operations
| - | - | - | (526.30M) | - |
Discontinued Operations
| - | - | - | (526.30M) | - |
Net Income After Extraordinaries
| 1.50B | 1.52B | 1.40B | 874.60M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 1.50B | 1.52B | 1.40B | 874.60M | |
EPS (Basic)
| 2.4115 | 2.4586 | 2.3115 | 1.4633 | |
EPS (Basic) Growth
| +82.34% | +1.95% | -5.98% | -36.69% | |
Basic Shares Outstanding
| 623.30M | 619.00M | 606.70M | 597.70M | |
EPS (Diluted)
| 2.3813 | 2.4382 | 2.3013 | 1.4594 | |
EPS (Diluted) Growth
| +82.76% | +2.39% | -5.61% | -36.58% | |
Diluted Shares Outstanding
| 631.20M | 624.20M | 609.40M | 599.30M | |
EBITDA
| 1.77B | 1.87B | 1.81B | 1.60B | |
EBITDA Growth
| +23.91% | +5.38% | -2.92% | -11.86% | |
EBITDA Margin
| +33.90% | +34.73% | +30.22% | +29.41% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 79.441 | |
| Number of Ratings | 32 | Current Quarters Estimate | 0.617 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | 2.455 | |
| Last Quarter’s Earnings | 0.59 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.43 | Next Fiscal Year Estimate | 2.753 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 26 | 26 | 29 | 27 |
| Mean Estimate | 0.62 | 0.61 | 2.46 | 2.75 |
| High Estimates | 0.66 | 0.64 | 2.50 | 2.93 |
| Low Estimate | 0.60 | 0.59 | 2.42 | 2.57 |
| Coefficient of Variance | 2.19 | 2.03 | 0.86 | 2.43 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 12 | 12 | 11 |
| OVERWEIGHT | 3 | 2 | 4 |
| HOLD | 16 | 17 | 18 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Edwards Lifesciences Corp. - EW
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Edwards Lifesciences Corp. - EW
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 15, 2025 | Donald E. Bobo CVP,Strategy/Corp Development | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 15, 2025 | Donald E. Bobo CVP,Strategy/Corp Development | 56,706 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share | 2,567,647.68 |
| Apr 15, 2025 | Donald E. Bobo CVP,Strategy/Corp Development | 47,206 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.81 per share | 3,295,450.86 |
| Apr 9, 2025 | Daniel J. Lippis CVP, JAPAC | 23,163 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share | 1,048,820.64 |
| Apr 9, 2025 | Daniel J. Lippis CVP, JAPAC | 22,863 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.61 per share | 1,614,356.43 |
| Apr 9, 2025 | Daniel J. Lippis CVP, JAPAC | 330 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Bernard J. Zovighian CEO; Director | 10,436 | Bona fide gift | 0.00 |
| Mar 11, 2025 | Bernard J. Zovighian CEO; Director | 59,083 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.51 per share | 4,106,859.33 |
| Mar 11, 2025 | Bernard J. Zovighian CEO; Director | 65,247 | Bona fide gift | 0.00 |
| Mar 11, 2025 | Bernard J. Zovighian CEO; Director | 7,462 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Bernard J. Zovighian CEO; Director | 66,546 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share | 3,013,202.88 |
| Mar 3, 2025 | Scott B. Ullem CVP, Chief Financial Officer | 30,387 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.52 per share | 2,142,891.24 |
| Mar 3, 2025 | Scott B. Ullem CVP, Chief Financial Officer | 22,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Scott B. Ullem CVP, Chief Financial Officer | 38,147 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $71.38 per share | 2,722,932.86 |
| Mar 3, 2025 | Scott B. Ullem CVP, Chief Financial Officer | 41,637 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share | 1,885,323.36 |
| Feb 17, 2025 | Steven R. Loranger Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 17, 2025 | Steven R. Loranger Director | 60,372 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $76.42 per share | 4,613,628.24 |
| Feb 17, 2025 | Steven R. Loranger Director | 66,111 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.32 per share | 2,996,150.52 |
| Jul 11, 2024 | David T. Feinberg Director | 2,308 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 22, 2024 | Scott B. Ullem CVP, Chief Financial Officer | 61,875 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Edwards Lifesciences Corp. in the News
Medical-device makers gain amid return to normalcy
Many of the top large-cap device makers reported relatively rosy fourth-quarter earnings while issuing 2023 guidance that was above analyst expectations.